Capital Cell

Nuestro Director de Relaciones con Inversores, Marc Armet, estará presente en el próximo LifeTech Summit 2025 en Murcia. ¡Nos vemos allí!

There are many good reasons to invest in MDsim's groundbreaking Digital Twin technology for Spinal Surgery. Check out seasoned investor Stéphane Epin's testimonial on why he is investing heavily in this company. ⭐ Know more & invest here -> https://lnkd.in/dY4KcbTF ⭐ https://lnkd.in/dN8vsWtB

In short succession: Invivo Partners's portfolio company EsoBiotec and Pureos Bioventures' Araris Biotech AG announce > $1 billion licensing agreements with circa $400M upfront payments. Congratulations to these funds and companies for such great Exits, neat symptoms of a strong recovery in #biotechnology M&A activity.

Proud to support AtmosR's funding efforts, a project that combines financial potential and social impact like few others.

Startup en santé : comment financer sa croissance jusqu’à la Série A ? Capital Cell et Eurasanté vous invitent à un afterwork dédié aux solutions de financement adaptées aux startups du secteur santé, mardi 25 mars 2025 à 18h30 au HUB Eurasanté : https://lnkd.in/eyJdxPsW Table-ronde : Experts du Venture Accelerator, VC, Business Angel et Crowdfunding partageront leurs stratégies : ➡️ Sandrine Egron - 50Partners ➡️ Hugues RENAUT - Angels Santé ➡️ Mathieu Gilliard – Eurasanté ➡️ Claire Bendao - DNA FINANCE ➡️ Daniel Oliver - Capital Cell ➡️ Maximilien Vermandel - Hemerion Therapeutics Pitchs & Networking autour d’un cocktail 🎙️ MDsim – Roger Assaker (CEO) & Jordan Assaker (Neurochirurgien) 🎙️ Celeos SAS – Philippe Saudemont (CEO) ⚠️ Événement réservé aux acteurs de l’écosystème santé (entrepreneurs, investisseurs) sous validation après inscription. | Julien GILLET-DAUBIN

We are proud to share that AstraZeneca is acquiring EsoBiotec! As an early-stage company pioneering in vivo cell therapies, we are advancing a platform with the potential to transform treatment delivery. Today, we announced a definitive agreement to join AstraZeneca. Our ENaBL platform is designed to eliminate traditional cell therapies' complex, time-consuming manufacturing process—replacing it with a simple IV injection that can be administered in minutes rather than weeks. CAR-T and other autologous therapies have revolutionized cancer treatment, but their high costs, logistical challenges, and long production timelines limit patient access. EsoBiotec’s in vivo approach has the potential to streamline treatment delivery, reduce barriers, and bring cell therapy to more patients faster. The acquisition deal includes an upfront payment of $425M, with up to $575M in milestone-based payouts. EsoBiotec will operate as a wholly owned subsidiary of AstraZeneca, further advancing in vivo cell therapy innovation. This marks a significant step toward making next-generation cell therapies more scalable and accessible. Read the full announcement here: https://lnkd.in/eNt6Wxtf #biotech #celltherapy #invivotherapy #astrazeneca #regenerativemedicine

Why would you invest in a treatment for less than 4000 people per year? Can tiny markets can generate amazing returns for investors? Meet the world of #RareDiseases. From the desk of Daniel Oliver: check out the latest article from Capital Cell's famous #Friday #Newsletter Read the article here: https://lnkd.in/dxf9MqFs 👉 Join 20,000+ subscribers for the latest in biotech investment & innovation: https://lnkd.in/d7cUNvqm

🚨 New Investment Opportunity: AtmosR AtmosR is developing a new therapy for rare neurological diseases with no cure. Founded by patient families and backed by experts, the company targets three conditions caused by the same mechanism - toxic protein aggregates in the brain: 🔹 CCHS – Lifelong respiratory failure (3,000 patients) 🔹 Kennedy’s Disease – Progressive muscle degeneration (10,000 patients) 🔹 Huntington’s Disease – Cognitive and motor decline (200,000 patients) Preclinical studies show up to 50% reduction in toxic proteins. With Orphan Drug Designation eligibility, AtmosR is on the fast track to approval. Now raising €700,000, with possibility for overfunding, the company offers an investment opportunity with 20x+ exit potential. 📲 Learn more: https://lnkd.in/dH-RScXE

🚀 Exciting News: You Can Now Invest in MDsim! 🚀 At MDsim, we’ve been on a mission to transform spine care with cutting-edge technology. Over the past months, we successfully raised €2M in seed funding from professional investors. Along the way, we’ve seen incredible enthusiasm from spine surgeons, doctors, patients, and the broader community—people who truly understand the impact of back pain and the need for better solutions. That’s why we’re opening a crowdfunding opportunity on Capital Cell, allowing anyone to join our journey with as little as €1,000! 🌍 Why invest? ✅ A game-changing innovation in spine surgery planning ✅ A massive unmet need—millions suffer from back pain worldwide ✅ A chance to make an impact while supporting a cutting-edge medtech startup 🎯 Be part of the future of spine care. Invest now: https://lnkd.in/e9_wC8py 📺 Learn more about MDsim: https://lnkd.in/e_tu4aSj 💡 Make money while making good. Join us today! 💙 #InvestInHealthTech #SpineCare #Crowdfunding #MDsim #Spine #orthopedic #neurosurgery #medical #medtech #digitaltwin #AI #biomechanics #digitaltwin Capital Cell MDsim Hexagon AB Hexagon Manufacturing Intelligence

⏰ 𝗟𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲 𝘁𝗼 𝗶𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 Aspivix 𝗮𝗻𝗱 Verigraft! Aspivix has surpassed its target, reaching 123.8% with €2,661,855 raised from 336 investors, including leading institutional backers like 4FOX Ventures, HEMEX AG (which has invested €2.8M since Aspivix’s founding), and Zürcher Kantonalbank, Switzerland’s largest cantonal bank. Named by TIME Magazine as one of the 200 Best Inventions of 2024, Aspivix is revolutionizing women’s health and setting new industry standards. VERIGRAFT, a pioneer in personalized tissue therapies, has successfully raised nearly €500,000 from the Swedish government and three grants (including Eurostars), along with €445,000 raised on Capital Cell. The company is now gearing up for its Series A and offering investors a 30% value increase guarantee—ensuring a minimum 30% gain in the next funding round, regardless of its valuation. 👉 Join the Aspivix campaign here: https://lnkd.in/dbC5zCJ3 👉 Join the VERIGRAFT campaign here: https://lnkd.in/dMjTKpST Both campaigns are already in overfunding! Don't miss out on this opportunity before they close at midnight tomorrow.